Aimmune Therapeutics (AIMT) KOL Call Details the Palforzia Opportunity - RBC Capital
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay reiterated an Outperform rating on Aimmune Therapeutics (NASDAQ: AIMT) after hosting a KOL call with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
